Clinical Data's Q1 Revenues Rise 81 Percent on PGx Test Sales | GenomeWeb

NEW YORK (GenomeWeb News) – Clinical Data today reported that its first-quarter revenues increased 81 percent year over year, due to sales growth for its Familion genetic tests.

The Newton, Mass.-based drug and pharmacogenomic test developer brought in total revenues of $3.7 million for the three-month period ended June 30, compared with revenues of $2 million for the first quarter of 2008. Its revenues came from sales of its Familion genetic tests, which are sold by its PGx Health division.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.